Pharmaron Beijing Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Boliang Lou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage	95.1%
CEO tenure	8.1yrs
CEO ownership	n/a
Management average tenure	8.1yrs
Board average tenure	8.1yrs

Recent management updates

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Nov 15

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Sep 27

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Sep 20

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

May 12

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27

CEO Compensation Analysis

How has Boliang Lou's remuneration changed compared to Pharmaron Beijing's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥1b
Dec 31 2023	CN¥2m	CN¥2m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥1b
Jan 01 2023	n/a	n/a	CN¥1b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥8m	CN¥2m	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥1b
Dec 31 2020	CN¥4m	CN¥2m	CN¥1b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥865m
Mar 31 2020	n/a	n/a	CN¥594m
Dec 31 2019	CN¥3m	CN¥2m	CN¥547m
Sep 30 2019	n/a	n/a	CN¥437m
Jun 30 2019	n/a	n/a	CN¥378m
Mar 31 2019	n/a	n/a	CN¥346m
Dec 31 2018	CN¥3m	CN¥2m	CN¥333m

Compensation vs Market: Boliang's total compensation ($USD304.64K) is about average for companies of similar size in the CN market ($USD264.38K).

Compensation vs Earnings: Boliang's compensation has been consistent with company performance over the past year.

CEO

Boliang Lou (61 yo)

8.1yrs

Tenure

CN¥2,208,000

Compensation

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Boliang Lou	Chairman & CEO	no data	CN¥2.21m	no data
Xiaoqiang Lou	Co-Founder	8.1yrs	CN¥1.91m	5.66% CN¥ 2.4b
Bei Zheng	Executive VP & Executive Director	8.1yrs	CN¥1.60m	2.12% CN¥ 915.5m
Shing Chung Li	CFO & Secretary of the Board	no data	CN¥1.96m	no data
Hua Yang	Chief Scientific Officer & Deputy Manager	8.1yrs	CN¥1.85m	no data
Connie Sun	Senior VP & Global Head of Business Development of Small Molecules	no data	no data	no data
Celina Zhong	Senior Vice President of Human Resources	no data	no data	no data
Katherine Lee	Chief Business Officer	13.8yrs	no data	no data
Stephen Lewinton	Senior Vice President of UK Operations	no data	no data	no data
Jingqi Huang	Senior Vice President of In Vivo Pharmacology	no data	no data	no data
Mandy Xu	Senior Vice President of DMPK	2.9yrs	no data	no data
Sid Bhoopathy	Senior VP and US Head of Laboratory Services & CGT	3yrs	no data	no data

8.1yrs

Average Tenure

57yo

Average Age

Experienced Management: 300759's management team is seasoned and experienced (8.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Boliang Lou	Chairman & CEO	8.1yrs	CN¥2.21m	no data
Xiaoqiang Lou	Co-Founder	8.1yrs	CN¥1.91m	5.66% CN¥ 2.4b
Bei Zheng	Executive VP & Executive Director	8.1yrs	CN¥1.60m	2.12% CN¥ 915.5m
Kexin Yang	Chairman of the Supervisory Committee	8.1yrs	no data	no data
Jiaqing Li	Non Executive Director	8.1yrs	no data	no data
Kwan Hung Tsang	Independent Non Executive Director	5yrs	CN¥300.00k	no data
Lan Zhang	Employee Representative Supervisor	8.1yrs	no data	no data
Lihua Li	Independent Non Executive Director	2.2yrs	CN¥300.00k	0.0042% CN¥ 1.8m
Jian Yu	Independent Non Executive Director	4.3yrs	CN¥300.00k	no data
Shu Feng	Supervisor	3.9yrs	no data	no data
Qilin Zhou	Independent Non-Executive Director	2.2yrs	CN¥300.00k	no data

8.1yrs

Average Tenure

57yo

Average Age

Experienced Board: 300759's board of directors are considered experienced (8.1 years average tenure).

Pharmaron Beijing Management

Management criteria checks 4/4

Key information

Recent management updates

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd. Announces Executive Changes

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Recent updates

At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?

Price target increased by 10.0% to CN¥28.22

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.1% to CN¥25.66

Investor sentiment deteriorates as stock falls 25%

New minor risk - Share price stability

Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Investor sentiment improves as stock rises 17%

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Second quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.25 in 2Q 2023)

Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Price target decreased by 12% to CN¥22.71

Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024

Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

Pharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)

Pharmaron Beijing Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 14%

Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Price target decreased by 7.3% to CN¥29.29

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 16%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

Now 24% undervalued after recent price drop

Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 2Q 2022)

Price target decreased by 8.9% to CN¥35.78

Price target decreased by 9.2% to CN¥36.68

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023

Price target decreased by 10% to CN¥58.29

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued after recent price drop

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.21 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 10% to CN¥69.70

Consensus EPS estimates fall by 19%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 10% to CN¥75.56

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022

Executive VP & Executive Director recently sold CN¥21m worth of stock

President recently sold CN¥31m worth of stock

President recently sold CN¥72m worth of stock

President recently sold CN¥24m worth of stock

President recently sold CN¥41m worth of stock

President recently sold CN¥48m worth of stock

President recently sold CN¥131m worth of stock

Price target decreased to CN¥81.79

Less than half of directors are independent

Price target decreased to CN¥87.07

Price target decreased to CN¥91.49

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.

Third quarter 2022 earnings released

Price target decreased to CN¥94.38

Investor sentiment improved over the past week